Literature DB >> 31564445

Reply to: "Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma".

Paola Bertuccio1, Matteo Malvezzi2, Greta Carioli2, Dana Hashim3, Paolo Boffetta4, Hashem B El-Serag5, Carlo La Vecchia2, Eva Negri6.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31564445     DOI： 10.1016/j.jhep.2019.08.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.

Authors:  Stephen P Hack; Wendy Verret; Sohail Mulla; Bo Liu; Yulei Wang; Teresa Macarulla; Zhenggang Ren; Anthony B El-Khoueiry; Andrew X Zhu
Journal:  Ther Adv Med Oncol       Date:  2021-07-31       Impact factor: 8.168

2.  CHST4 might promote the malignancy of cholangiocarcinoma.

Authors:  Guanran Zhang; Xuyue Liu; Aiwen Jian; Kexin Zheng; Haiyan Wang; Jing Hao; Sujuan Zhi; Xiaoli Zhang
Journal:  PLoS One       Date:  2022-03-16       Impact factor: 3.240

3.  The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma.

Authors:  Margherita Correnti; Andrea Cappon; Mirella Pastore; Benedetta Piombanti; Giulia Lori; Douglas V P N Oliveira; Patricia Munoz-Garrido; Monika Lewinska; Jesper B Andersen; Cédric Coulouarn; Laurent Sulpice; Caterina Peraldo Neia; Giuliana Cavalloni; Santina Quarta; Alessandra Biasiolo; Matteo Fassan; Matteo Ramazzotti; Matteo Parri; Stefania Recalcati; Luca di Tommaso; Claudia Campani; Pietro Invernizzi; Guido Torzilli; Fabio Marra; Patrizia Pontisso; Chiara Raggi
Journal:  Liver Int       Date:  2021-09-16       Impact factor: 8.754
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.